

SIGLEC5 Antibody (N-term) Blocking Peptide
Synthetic peptide
Catalog # BP16649a**Specification**

SIGLEC5 Antibody (N-term) Blocking Peptide - Product InformationPrimary Accession [O15389](#)**SIGLEC5 Antibody (N-term) Blocking Peptide - Additional Information****Gene ID** 8778**Other Names**

Sialic acid-binding Ig-like lectin 5, Siglec-5, CD33 antigen-like 2, Obesity-binding protein 2, OB-BP2, OB-binding protein 2, CD170, SIGLEC5, CD33L2, OBBP2

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

SIGLEC5 Antibody (N-term) Blocking Peptide - Protein Information**Name** SIGLEC5**Synonyms** CD33L2, OBBP2**Function**

Putative adhesion molecule that mediates sialic-acid dependent binding to cells. Binds equally to alpha-2,3-linked and alpha-2,6-linked sialic acid. The sialic acid recognition site may be masked by cis interactions with sialic acids on the same cell surface.

Cellular Location

Membrane; Single-pass type I membrane protein.

Tissue Location

Expressed by monocytic/myeloid lineage cells. Found at high levels in peripheral blood leukocytes, spleen, bone marrow and at lower levels in lymph node, lung, appendix, placenta, pancreas and thymus. Expressed by monocytes and neutrophils but absent from leukemic cell lines representing early stages of myelomonocytic differentiation

SIGLEC5 Antibody (N-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

SIGLEC5 Antibody (N-term) Blocking Peptide - Images

SIGLEC5 Antibody (N-term) Blocking Peptide - Background

The sialic acid-binding immunoglobulin-like lectins (SIGLECs), such as SIGLEC5, are a subgroup of the immunoglobulin (Ig) superfamily that mediate protein-carbohydrate interactions. They specifically interact with sialic acids in glycoproteins and glycolipids, with each SIGLEC having a particular preference for both the nature of the sialic acid and its glycosidic linkage to adjacent sugars. SIGLECs have similar structures, including extracellular Ig-like domains composed of an N-terminal V-set domain followed by varying numbers of C2-set domains. It appears that all SIGLECs have an unusual arrangement of conserved cysteine residues in the V-set and adjacent C2-set domains. Most SIGLECs are expressed uniquely within the hematopoietic system (Cornish et al., 1998 [PubMed 9731071]).

SIGLEC5 Antibody (N-term) Blocking Peptide - References

Soto, P.C., et al. J. Immunol. 184(8):4185-4195(2010) Davila, S., et al. Genes Immun. 11(3):232-238(2010) Carlin, A.F., et al. J. Exp. Med. 206(8):1691-1699(2009) Zhuravleva, M.A., et al. J. Mol. Biol. 375(2):437-447(2008) Gunnarsson, P., et al. FASEB J. 21(14):4059-4069(2007)